dovitinib lactate + gemcitabine hydrochloride + capecitabine
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma of the Pancreas
Conditions
Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Trial Timeline
Mar 29, 2012 → Feb 7, 2017
NCT ID
NCT01497392About dovitinib lactate + gemcitabine hydrochloride + capecitabine
dovitinib lactate + gemcitabine hydrochloride + capecitabine is a phase 1 stage product being developed by Novartis for Adenocarcinoma of the Pancreas. The current trial status is completed. This product is registered under clinical trial identifier NCT01497392. Target conditions include Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Adenocarcinoma of the Pancreas were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01497392 | Phase 1 | Completed |
Competing Products
20 competing products in Adenocarcinoma of the Pancreas